Physician profile
Paul Eric Evans
NPI 1275557589
$4,643.33
in general payments reported to CMS, 2019-2025
42 companies · $694 in 2025
The $694 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $294 · 2021: $594 · 2022: $1,033 · 2023: $732 · 2024: $671 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.42 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $628.64 | 2022-2025 | |
| Astellas Pharma US INC | $473.15 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $321.86 | 2021-2025 | Slynd |
| Aspira Women'S Health INC | $209.44 | 2022-2024 | Ova1 |
| Baxter Healthcare | $174.81 | 2022-2024 | Starling System |
| Sumitomo Pharma America, INC. | $156.35 | 2023-2025 | Myfembree, Gemtesa |
| Daiichi Sankyo INC. | $139.94 | 2019-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $116.06 | 2019-2020 | |
| Therapeuticsmd, INC. | $114.07 | 2020-2022 | |
| Allergan, INC. | $101.67 | 2019-2020 | |
| Boston Scientific Corporation | $100.67 | 2023 | Solyx Sis System |
| Shield Therapeutics INC | $94.01 | 2024-2025 | |
| Novo Nordisk INC | $79.86 | 2019-2023 | Saxenda, Wegovy |
| Avion Pharmaceuticals | $79.47 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.